Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

Literature DB >> 24335039

Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

Tamio Teramoto¹, Jun Sasaki, Shun Ishibashi, Sadatoshi Birou, Hiroyuki Daida, Seitaro Dohi, Genshi Egusa, Takafumi Hiro, Kazuhiko Hirobe, Mami Iida, Shinji Kihara, Makoto Kinoshita, Chizuko Maruyama, Takao Ohta, Tomonori Okamura, Shizuya Yamashita, Masayuki Yokode, Koutaro Yokote.

Abstract

Entities: Disease

Mesh：

Year: 2013 PMID： 24335039 DOI： 10.5551/jat.19166

Source DB: PubMed Journal: J Atheroscler Thromb ISSN： 1340-3478 Impact factor: 4.928

Keyword Cloud
Cited

× No keyword cloud information.

4 in total

1. Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab.

Authors: Akihito Tanaka; Daijo Inaguma; Yu Watanabe; Eri Ito; Naoki Kamegai; Hiroya Shimogushi; Hibiki Shinjo; Kiyomi Koike; Yasuhiro Otsuka; Asami Takeda
Journal: Intern Med Date: 2017-06-15 Impact factor: 1.271

Authors: Terry A Jacobson; Steven V Edelman; Nina Galipeau; Alan L Shields; Usha G Mallya; Andrew Koren; Michael H Davidson
Journal: Patient Date: 2017-06 Impact factor: 3.883

3. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.

Authors: Tamio Teramoto; Akira Kondo; Arihiro Kiyosue; Mariko Harada-Shiba; Yasushi Ishigaki; Kimimasa Tobita; Yumiko Kawabata; Asuka Ozaki; Marie T Baccara-Dinet; Masataka Sata
Journal: Lipids Health Dis Date: 2017-06-17 Impact factor: 3.876

4. Statin use and all-cause and cancer mortality: BioBank Japan cohort.

Authors: Hiroshi Yokomichi; Akiko Nagai; Makoto Hirata; Akiko Tamakoshi; Yutaka Kiyohara; Yoichiro Kamatani; Kaori Muto; Toshiharu Ninomiya; Koichi Matsuda; Michiaki Kubo; Yusuke Nakamura; Zentaro Yamagata
Journal: J Epidemiol Date: 2017-02-11 Impact factor: 3.211

4 in total

Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.

1. Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab.

2. Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©.

3. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.

4. Statin use and all-cause and cancer mortality: BioBank Japan cohort.